ZA201908165B - Compounds for the prevention and treatment of diseases and the use thereof - Google Patents

Compounds for the prevention and treatment of diseases and the use thereof

Info

Publication number
ZA201908165B
ZA201908165B ZA2019/08165A ZA201908165A ZA201908165B ZA 201908165 B ZA201908165 B ZA 201908165B ZA 2019/08165 A ZA2019/08165 A ZA 2019/08165A ZA 201908165 A ZA201908165 A ZA 201908165A ZA 201908165 B ZA201908165 B ZA 201908165B
Authority
ZA
South Africa
Prior art keywords
diseases
prevention
compounds
treatment
Prior art date
Application number
ZA2019/08165A
Other languages
English (en)
Inventor
Eliezer Zomer
Peter G Traber
Raphael Nir
Sharon Shechter
Joseph M Johnson
Ryan George
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of ZA201908165B publication Critical patent/ZA201908165B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA2019/08165A 2017-05-12 2019-12-09 Compounds for the prevention and treatment of diseases and the use thereof ZA201908165B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (1)

Publication Number Publication Date
ZA201908165B true ZA201908165B (en) 2023-07-26

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/08165A ZA201908165B (en) 2017-05-12 2019-12-09 Compounds for the prevention and treatment of diseases and the use thereof

Country Status (12)

Country Link
US (2) US11576924B2 (enExample)
EP (1) EP3621973A4 (enExample)
JP (1) JP7204676B2 (enExample)
KR (1) KR102626669B1 (enExample)
CN (1) CN110869378B (enExample)
AU (1) AU2018265571B2 (enExample)
BR (1) BR112019023722A2 (enExample)
CA (1) CA3062648A1 (enExample)
IL (1) IL270469B2 (enExample)
MX (1) MX392945B (enExample)
WO (1) WO2018209255A1 (enExample)
ZA (1) ZA201908165B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117883A1 (en) * 2018-12-06 2020-06-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP7547345B2 (ja) * 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
EP3947407B1 (en) 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
US12275720B2 (en) 2020-05-05 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2021231243A1 (en) 2020-05-11 2021-11-18 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CN115768768A (zh) 2020-05-28 2023-03-07 百时美施贵宝公司 半乳凝素-3抑制剂
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン-カルバモイル誘導体
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9626450D0 (en) * 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
GB0501008D0 (en) 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
AU2007319806A1 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of TIM-3 modulators
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
EA201270316A1 (ru) 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2848711C (en) 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
CN104245717B (zh) 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (enExample) * 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
EP3125908A4 (en) 2014-03-10 2017-11-15 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US10799522B2 (en) 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
US20190367552A1 (en) * 2016-03-04 2019-12-05 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Also Published As

Publication number Publication date
US20230132265A1 (en) 2023-04-27
IL270469A (enExample) 2019-12-31
AU2018265571B2 (en) 2022-09-29
WO2018209255A1 (en) 2018-11-15
EP3621973A4 (en) 2021-10-27
JP7204676B2 (ja) 2023-01-16
AU2018265571A1 (en) 2019-12-05
EP3621973A1 (en) 2020-03-18
US11576924B2 (en) 2023-02-14
CN110869378A (zh) 2020-03-06
JP2020519625A (ja) 2020-07-02
CA3062648A1 (en) 2018-11-15
IL270469B1 (en) 2023-03-01
KR20200016246A (ko) 2020-02-14
MX392945B (es) 2025-03-19
US20200155586A1 (en) 2020-05-21
BR112019023722A2 (pt) 2020-05-26
MX2019013537A (es) 2020-02-13
IL270469B2 (en) 2023-07-01
KR102626669B1 (ko) 2024-01-17
CN110869378B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
IL270469B1 (en) Compounds for the prevention and treatment of diseases and their use
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL266047A (en) Methods and preparations for the treatment of Fabry disease
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL269083A (en) Methods for preventing and treating heart disease
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
GB201715194D0 (en) Compounds and their therapeutic use
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
PT3191112T (pt) Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
PL3490604T3 (pl) Środek leczniczy do leczenia i/lub zapobiegania endometriozie
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency